Table 2. Reciprocal NtAb titers against homotypic and heterotypic pp in HCV genotype 1a infections.
Patient H
|
Ch 1530
|
|||||||
---|---|---|---|---|---|---|---|---|
Week 9 | Year 2 | Year 26 | Ch1581, year 2 | Week 21 | Year 1 | Year 3 | Ch1422, year 18 | |
ppH77(1a) | 200 | 400 | 3,200 | 800 | 50 | 400 | ≈50 | 50 |
ppJ6CF(2a) | <50 | ≈50 | 100 | <50 | <50 | <50 | <50 | <50 |
ppS52(3a) | <50 | <50 | <50 | <50 | <50 | <50 | <50 | 50 |
ppED43(4a) | <50 | 400 | 6,400 | 50 | <50 | 100 | 50 | <50 |
ppSA13(5a) | <50 | 800 | 6,400 | 200 | <50 | <50 | <50 | <50 |
ppHK(6a) | <50 | 800 | 6,400 | 200 | <50 | <50 | <50 | <50 |
Titers were determined by serial 2-fold dilutions of chimpanzee or human sera from genotype 1a infection and subsequent incubation with the indicated HCVpp. Values for neutralization of ppH77(1a) with sample collected from Ch 1530 at year 3 and cross-neutralization of ppJ6CF(2a) with sample collected from patient H at year 2 are indicated as ≈50 because it was repeatedly detected either slightly more or less than 50.